Company profile
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of
- CEO
- Dr. Malte Peters M.D.
- Headquarters
- New York, NY, United States
- Employees
- 82
- IPO date
- Apr 18, 2019
- Sector
- Healthcare
- Industry
- Biotechnology